Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Bluebird Bio Turned in a Disappointing 2015

By George Budwell - Jan 9, 2016 at 9:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bluebird bio's shares shed almost a third of their value last year. Unfortunately, the stock may still have further to drop as several competitors race to cure a diversity of blood-based disorders.

BLUE Chart

BLUE data by YCharts.

What: After starting the year off at a blistering pace, the clinical-stage gene therapy company bluebird bio (BLUE -13.25%) broke down in the second half of the year, finishing 2015 down by around 30%, according to S&P Capital IQ.

Although the troubling macroeconomic and geopolitical environments probably weighed on bluebird's annual performance, the news that the company's lead gene therapy candidate, LentiGlobin BB305, didn't appear to work all that well in patients with the most severe forms of the inherited blood disorder, beta-thalassemia, was likely the main culprit. 

In fact, bluebird bio's stock dropped a whopping 20% the day after the company's abstracts for the American Society of Hematology (ASH) meeting were released last November, revealing this disappointing clinical news. 

So what: Initially, LentiGlobin BB305 looked like it could be a functional cure for this rare disease, giving investors hope that it might turn into a blockbuster product, depending on its pricing scheme. As the clinical data continues to trickle out, though, it's starting to look like LentiGlobin BB305 might only be a truly effective treatment in milder cases of the disorder, significantly curtailing its commercial potential in the beta-thalassemia space. 

Now what: Bluebird's researchers noted in their presentation at ASH that it's still too early to draw any solid conclusions regarding LentiGlobin BB305's effectiveness in the most severe cases of beta-thalassemia. Regardless of the ultimate outcome, though, bluebird's lead gene therapy may end getting pushed aside in 2016 by Bellicum Pharmaceuticals' (BLCM 0.00%) experimental cell therapy BPX-501.

BPX-501 is presently in the midst of early and mid-stage testing in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for a variety of blood disorders, including beta-thalassemia. The basic issue to understand is that allogeneic HSCT is essentially a curative treatment for beta-thalassemia, but it's rarely performed because of potentially deadly side effects such as graft-versus-host disease and viral infection.

Bellicum's goal is use BPX-501 to make this procedure safer, allowing a much wider swath of patients to gain access to a functional cure. If Bellicum or any of the other companies working on similar treatments are successful, bluebird's most advanced product candidate may turn out to have limited commercial upside.

That's not to say that one of these cell therapy companies is destined to succeed in this endeavor, only that bluebird shareholders should definitely consider this emerging risk going forward. 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$5.50 (-13.25%) $0.84
Bellicum Pharmaceuticals, Inc. Stock Quote
Bellicum Pharmaceuticals, Inc.
BLCM
$1.34 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.